Q: CMB Monaco has a long-standing tradition of supporting charitable initiatives. Could you tell us more about this year’s partnership with Cancer Research UK?

Francesco Grosoli: As we approach the festive season - a time associated with generosity and togetherness - we wanted once again to stand for a cause that truly matters. This year, we are proud to partner with Cancer Research UK, one of the world’s leading charities dedicated to fighting cancer through groundbreaking research and innovation.

Our contribution will support research specific to cancers that affect children and young people, with the aim of improving outcomes for this age group. Supporting a cause that gives hope to younger generations deeply resonates with our values as a private bank rooted in family, legacy and care.

Q: This initiative follows several years of CMB Monaco’s commitment to children’s causes. How has this effort evolved over time?

Francesco Grosoli: This is the fourth consecutive year that we dedicate our end-of-year initiative to organisations supporting children. Over the past three years, nearly €100,000 has been raised, last year alone reaching a record of €41,431.

What matters most to us is that these funds represent a collective effort. Every employee and every client contribution makes a difference, and together we’ve built something that extends far beyond banking, it’s a shared movement of compassion and responsibility.

Q: Cancer Research UK is one of the world’s leading cancer charities dedicated to saving and improving lives with its research. Could you tell us more about your mission and the specific work you are funding in children’s and young people’s cancer research?

Michelle Mitchell: Our vision is to bring about a world where everybody lives longer, better lives, free from the fear of cancer. To achieve this, we fund scientists, researchers and clinicians who carry out research into more than 200 types of cancer, making discoveries about cancer that unlock new and better ways to beat it. These discoveries are translated into new tests, treatments and prevention measures that can save and improve lives around the world.

One of our focus areas is cancer that affects children and young people and we’re very grateful to have the support of CMB Monaco, its staff, partners and clients. Our research has played a role in around half of the world’s cancer drugs considered essential for children (12 and younger) but each year, around 400,000 children and young people worldwide are diagnosed with the disease. We are determined to change the outlook for these people and their families.

Q: What impact can partnerships like the one with CMB Monaco have on advancing your research and supporting families affected by cancer?

Michelle Mitchell: Collaborating with likeminded organisations enables us to have the greatest possible impact. Thanks to the support and generosity of partners like CMB Monaco, we can invest in more pioneering research that has the potential to accelerate progress and improve and save lives.

Cancer is different in children and young people – from the types of cancer that affect this age group to the long-term effects of treatment and challenges holding back progress – so it needs a different and dedicated approach. It requires global collaboration across different sectors and critically, it requires funding. Partnerships of this nature bring us closer to helping more children and young people with cancer live better lives through more effective and less toxic treatments.